Popular DNA testing firm 23andMe has filed for bankruptcy protection, marking a significant downturn for the company that once boasted a valuation of $6 billion. The announcement comes alongside the resignation of co-founder and CEO Anne Wojcicki, as the company seeks to navigate its financial challenges under court supervision.
Key Takeaways
- 23andMe has filed for bankruptcy protection and is seeking a buyer.
- CEO Anne Wojcicki has resigned, with Joe Selsavage stepping in as interim CEO.
- The company has faced significant financial struggles and a recent data breach affecting customer privacy.
- Customers are advised to consider deleting their data from the platform.
Company Background
Founded in 2006, 23andMe revolutionised the personal genomics industry with its saliva-based DNA testing kits. The company went public in 2021 but has struggled to achieve profitability since its inception. Despite high-profile endorsements from celebrities like Oprah Winfrey and Snoop Dogg, the firm has faced mounting challenges in recent years.
Financial Distress and Data Breach
In September 2023, 23andMe settled a lawsuit related to a data breach that exposed the personal information of nearly seven million customers. Although the stolen data did not include DNA records, it raised serious concerns about the company’s ability to protect sensitive information. Following the breach, the company laid off 200 employees, representing 40% of its workforce, as part of cost-cutting measures.
Leadership Changes
With Wojcicki’s resignation, Joe Selsavage, the company’s finance chief, will take over as interim CEO. Wojcicki will remain on the board but had previously attempted to take the company private, rejecting third-party buyout offers. The board chair, Mark Jensen, has assured customers that the company remains committed to safeguarding user data during this transition.
Customer Concerns
In light of the bankruptcy filing, the California Attorney General has issued a consumer alert, advising customers to delete their data from the site due to the company’s financial instability. This has raised concerns about the future of the genetic data shared by users, especially given the legal protections surrounding such sensitive information in various jurisdictions.
Future Prospects
As 23andMe embarks on the sale process, it aims to continue operations without interruption. However, the company’s struggle to redefine its business model has left many questioning its viability. Efforts to launch a subscription service and pivot towards drug development have not yielded the expected results, leaving the firm at a crossroads.
Conclusion
The bankruptcy filing of 23andMe highlights the challenges faced by companies in the personal genomics sector, particularly in maintaining customer trust and financial stability. As the company navigates this turbulent period, the fate of its operations and the data of millions of customers hangs in the balance.
